Abstract: The present disclosure is directed to relates to systems and methods for evaluating tissue using high intensity focused ultrasound (HIFU) energy. In one embodiment, for example, a system for treating a patient comprises an ultrasound source configured to deliver HIFU energy to a target tissue mass of the patient and a function generator operably coupled to the ultrasound source for initiating a pulsing protocol for delivering the HIFU energy. The system further comprises a controller configured to perform operations comprising applying HIFU energy to induce cavitation in the target tissue mass and cause a biomarker to be released, comparing a baseline concentration of the biomarker from a first fluid sample to a concentration of the biomarker in a second fluid sample within 2 hours after applying HIFU, and repeating the applying and comparing until the concentration of the biomarker in the fluid sample falls below a threshold value.

Abstract: Systems and methods for enhancing infection detection and monitoring through decomposed physiological data are disclosed. An example method includes receiving, from a wearable device of a user, physiological data of the user and decomposing the physiological data, by applying a heart rate algorithm, to generate one or more physiological parameters. The example method further includes analyzing, by applying the heart rate algorithm, the one or more physiological parameters to output a period classification, and determining whether or not the period classification is indicative of an infection. The example method further includes, responsive to determining that the period classification is indicative of the infection, displaying, in a user interface, a warning to the user that indicates the infection, and receiving, from the wearable device of the user, additional physiological data of the user to monitor the infection.

Abstract: The present disclosure provides methods, systems, and kits for detecting molecules in a sample with a pre-equilibrium digital immunoassay. The methods and systems provide means for quantifying molecules in a biological sample of minimal volume in short amounts of time.

Abstract: Provided herein is technology relating to detecting and identifying nucleic acids and particularly, but not exclusively, to compositions, methods, kits, and systems for detecting, identifying, and quantifying target nucleic acids with high confidence at single-molecule resolution.

Abstract: Provided herein is technology relating to detecting analytes and particularly, but not exclusively, to methods, compositions and systems for detecting, characterizing, identifying, and/or quantifying analytes.

Abstract: Provided herein is technology relating to the detection of analytes and particularly, but not exclusively, to methods, systems, compositions, and kits for detecting analytes such as nucleic acids, proteins, small molecules, metabolites, and other molecules using a technology based on the transient binding of detection probes in combination with a microfluidic device and/or a nanoparticle.

Abstract: The present disclosure is directed to relates to systems and methods for evaluating tissue using high intensity focused ultrasound (HIFU) energy. In one embodiment, for example, a system for treating a patient comprises an ultrasound source configured to deliver HIFU energy to a target tissue mass of the patient and a function generator operably coupled to the ultrasound source for initiating a pulsing protocol for delivering the HIFU energy. The system further comprises a controller configured to perform operations comprising applying HIFU energy to induce cavitation in the target tissue mass and cause a biomarker to be released, comparing a baseline concentration of the biomarker from a first fluid sample to a concentration of the biomarker in a second fluid sample within 2 hours after applying HIFU, and repeating the applying and comparing until the concentration of the biomarker in the fluid sample falls below a threshold value.

Abstract: Provided herein is technology relating to detection of analytes and particularly, but not exclusively, to compositions, methods, and systems for concentrating an analyte at a surface, e.g., for imaging and detection of low-abundance analytes.

Abstract: Provided herein is technology relating to detecting and identifying nucleic acids and particularly, but not exclusively, to compositions, methods, kits, and systems for detecting, identifying, and quantifying target nucleic acids with high confidence at single-molecule resolution.

Abstract: Provided herein is technology relating to the detection of analytes and particularly, but not exclusively, to methods, systems, compositions, and kits for detecting analytes such as nucleic acids, proteins, small molecules, and other molecules using a technology based on the transient binding of detection probes.

Abstract: The present disclosure provides methods of performing a liquid molecular biopsy on a subject using high intensity focused ultrasound (HIFU) energy. The present disclosure also provides methods of diagnosing a disease or a risk of a disease, such as a cancer, in a subject. The present disclosure further provides methods of treating one or more tissue masses (e.g., nodules, tumors, cysts, lesions, cells of unknown significance etc.) in a subject. In some embodiments, the methods are non-invasive or minimally invasive.

Abstract: Stable, extracellular microRNAs and methods for isolating and identifying such microRNAs from a body fluid are provided. The extracellular microRNAs isolated from a bodily fluid of a subject can be used to measure disease and provide sensitive, efficient, and non invasive methods for the detection of disease, including cancer. The extracellular microRNAs can be used to develop new therapeutics for the treatment of disease, including cancer. The examples illustrate diagnosis of prostate and ovarian cancer and differential expression of miR-100, miR-135b, miR-141, miR-148a, miR-200a, miR-200c, miR-210, miR-222, miR-375, miR-425-Sp and miR-429.